Witryna4 gru 2024 · First-line durvalumab plus platinum–etoposide showed sustained overall survival improvement versus platinum–etoposide but the addition of tremelimumab to durvalumab plus platinum–etoposide did not significantly improve outcomes versus platinum–etoposide. These results support the use of durvalumab plus … Witryna14 maj 2024 · Methods: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit.
Nivolumab + Ipilimumab in der Erstlinientherapie des …
WitrynaImmPower AHCC Immune System Support Mushroom Extract - American BioSciences, Inc. ImmPower® AHCC® Immune System Support $ 54.95 Where to Purchase Size: 30 capsules/bottle Active Ingredients: 500 mg AHCC proprietary blend. – Maintains peak Natural Killer cell function. – Supports enhances cytokine production. WitrynaIMPower150 In die Phase-III-Studie IMPower150 wurden 1202 Patienten 1 : 1 : 1 auf drei Arme verteilt ( Tab. 1 ). Ko-primäre Endpunkte waren das Gesamt (OS)- und das progressionsfreie Überleben (PFS) in der Wildtyp-Intent-to-Treat-Population. Die Studie ist noch nicht abgeschlossen. csl1103wbbw1
IMpower010 Update: Adjuvant Atezolizumab Extends DFS in …
Witryna14 maj 2024 · Ensuring Public Trust in an Empowered FDA Editorial CAR T Cells for Neuroblastoma Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in … WitrynaIMpower010研究既往公布的数据主要是无病生存期（DFS）的结果，研究显示阿替利珠单抗辅助治疗，用于PD-L1肿瘤细胞（TC）表达≥1%，且经手术切除和以铂类为基础辅助化疗后的II-IIIA期患者，具有显著的DFS获益，患者疾病复发或死亡风险降低34%（DFS HR=0.66,P=0.004），治疗组患者的3年DFS率达到60% [1] 。 基于以上数据，阿替 … Witryna12 cze 2024 · IMpower150: Atezo + CT + Bev in NSCLC - Capsule Summary Slidesets - Lung Cancer - 2024 ASCO Annual Meeting - Oncology - Clinical Care Options IMpower150 Interim OS Analysis: Atezolizumab + CT ± Bevacizumab vs CT + Bevacizumab in Patients With Untreated Advanced Nonsquamous NSCLC Source: … csl 1084 syndicate